Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.

UNLABELLED The aim of this study was to evaluate, whether PET with (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) may be used to monitor noninvasively the antiproliferative effects of tyrosine kinase inhibitors. METHODS Using a high-resolution small animal scanner, we measured the effect of the ErbB-selective kinase inhibitor PKI-166 on the (18)F-FDG and (18)F-FLT uptake of ErbB1-overexpressing A431 xenograft tumors. RESULTS Treatment with PKI-166 markedly lowered tumor (18)F-FLT uptake within 48 h of drug exposure; within 1 wk (18)F-FLT uptake decreased by 79%. (18)F-FLT uptake by the xenografts significantly correlated with the tumor proliferation index as determined by proliferating cell nuclear antigen staining (r = 0.71). Changes in (18)F-FLT uptake did not reflect inhibition of ErbB kinase activity itself but, rather, the effects of kinase inhibition on tumor cell proliferation. Tumor (18)F-FDG uptake generally paralleled the changes seen for (18)F-FLT. However, the baseline signal was significantly lower than that for (18)F-FLT. CONCLUSION These results indicate that (18)F-FLT PET provides noninvasive, quantitative, and repeatable measurements of tumor cell proliferation during treatment with ErbB kinase inhibitors and provide a rationale for the use this technology in clinical trials of kinase inhibitors.

[1]  Michael E Phelps,et al.  Positron emission tomography scanning: current and future applications. , 2002, Annual review of medicine.

[2]  Q. She,et al.  Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  A. Ullrich,et al.  Metabolic effects induced by epidermal growth factor (EGF) in cells expressing EGF receptor mutants. , 1989, The Journal of biological chemistry.

[4]  J. Mestan,et al.  AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. , 2004, Cancer research.

[5]  L. Wiens,et al.  Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  Elias S. J. Arnér,et al.  Mammalian deoxyribonucleoside kinases. , 1995, Pharmacology & therapeutics.

[7]  C. W. Alvord,et al.  Tantalum [18O]water target for the production of [18F]fluoride with high reactivity for the preparation of 2-deoxy-2-[18F]fluoro-D-glucose. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[8]  Bengt Långström,et al.  Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  H. Lodish.  Molecular Cell Biology , 1986 .

[10]  Mark Muzi,et al.  In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  M. Schwaiger,et al.  Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Dence,et al.  Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  C. Sawyers.  Opportunities and challenges in the development of kinase inhibitor therapy for cancer. , 2003, Genes & development.

[14]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[15]  W. Vaalburg,et al.  Detection and Grading of Soft Tissue Sarcomas of the Extremities with 18F-3′-Fluoro-3′-Deoxy-l-Thymidine , 2004, Clinical Cancer Research.

[16]  J. Mendelsohn.  Targeting the epidermal growth factor receptor for cancer therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. R. Grierson,et al.  Simplified Labeling Approach for Synthesizing 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT) , 2000 .

[18]  D. Visvikis,et al.  Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  H. Dittmann,et al.  [18F]FLT PET for diagnosis and staging of thoracic tumours , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[21]  Torsten Mattfeldt,et al.  Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  K. Krohn,et al.  Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  M. Karin,et al.  Mammalian MAP kinase signalling cascades , 2001, Nature.

[24]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[25]  Sven N Reske,et al.  3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. , 2003, Cancer research.

[26]  R. N. Goble,et al.  Performance evaluation of the microPET P4: a PET system dedicated to animal imaging. , 2001, Physics in medicine and biology.

[27]  H. Lehväslaiho,et al.  Activation of the neu tyrosine kinase induces the fos/jun transcription factor complex, the glucose transporter and ornithine decarboxylase , 1989, The Journal of cell biology.

[28]  H. Machulla,et al.  Synthesis and labeling of 5'-O-(4,4'-dimethoxytrityl)-2,3'-anhydr othymidine for [18F]FLT preparation , 2002 .

[29]  K. Krohn,et al.  Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3'-deoxy-3'fluorothymidine uptake. , 2004, Nuclear medicine and biology.

[30]  R. Then,et al.  Thymidine concentrations in serum and urine of different animal species and man. , 1977, Biochemical pharmacology.

[31]  Ronald G Blasberg,et al.  Molecular-genetic imaging: current and future perspectives. , 2003, The Journal of clinical investigation.

[32]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[33]  I. Mellinghoff,et al.  Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. , 2002, Cancer research.

[34]  D. Visvikis,et al.  In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography , 2003, Gut.

[35]  Qimin He,et al.  3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. , 2003, Cancer research.

[36]  Y. Yonekura,et al.  Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. , 2002, Nuclear medicine and biology.

[37]  W. Mikulits,et al.  Overexpression of Thymidine Kinase mRNA Eliminates Cell Cycle Regulation of Thymidine Kinase Enzyme Activity (*) , 1996, The Journal of Biological Chemistry.